Palvella Therapeutics Appoints Key Rare Disease Commercial Leader to Drive Market Access Ahead of QTORIN™ Launch
PVLA has more than doubled off its 52-week low of $18.225.
Summary
Palvella Therapeutics has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services. This is a significant strategic hire for Palvella as it prepares for a potential near-term U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations. Ms. McDonough brings over 25 years of rare disease commercial experience, including leading the successful U.S. launch of VYJUVEK® at Krystal Biotech, which achieved $389 million in annual sales. Her expertise in market access, patient support, and specialty distribution is crucial for Palvella to build out its commercial infrastructure and ensure patient access for its pipeline therapies.
At the time of this announcement, PVLA was trading at $112.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.23 to $151.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.